蛋白质组学技术在药物性肝损伤生物标志物研究中的应用

发布时间：2018-08-28 09:10

【摘要】：临床前药物性肝损伤的评价存在灵敏性低和特异性差的问题,常产生假阴性结果和出现意外的毒性,是导致药物终止开发甚至退市的重要原因之一。在药物肝毒性临床前研究中,可以利用蛋白质组学技术的快速、灵敏、高通量等优点,寻找和发现新的肝毒性生物标志物,使药物开发过程更为安全有效。本文对肝毒性生物标志物的研究现状,蛋白质组学在生物标志物的发现及验证等方面的技术发展进行了综述分析,并且着重归纳了该技术在中药致肝损伤方面的生物标志物研究中的应用。与传统评价方法相比,蛋白质组学技术对于发现新型肝潜在毒性生物标志物具有不可替代的优势。随着蛋白质组学技术结合其他组学技术的发展,其在药物肝毒性早期筛选、生物标志物的临床桥接等方面将取得突破性的进展。
[Abstract]:The evaluation of preclinical drug-induced liver injury has the problems of low sensitivity and poor specificity, which often results in false negative results and accidental toxicity, which is one of the important reasons leading to the termination of drug development or even delisting from the market. In the preclinical study of drug hepatotoxicity, the advantages of proteomics, such as rapid, sensitive and high-throughput, can be used to find and find new biomarkers of hepatotoxicity, so that the development process of drugs can be more safe and effective. In this paper, the research status of hepatotoxicity biomarkers and the development of proteomics in the discovery and verification of biomarkers were reviewed and analyzed. The application of this technique in the study of biomarkers of liver injury caused by traditional Chinese medicine was summarized. Compared with traditional evaluation methods, proteomics has irreplaceable advantages in the discovery of new potential liver toxicity biomarkers. With the development of proteomics combined with other techniques, it will make a breakthrough in the early screening of drug hepatotoxicity and the clinical bridging of biomarkers.
【作者单位】：上海中医药大学药物安全评价研究中心;
【基金】：国家科技重大专项(2012ZX09505001-002)~~
【分类号】：R575

【相似文献】